Aktis Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Aktis Oncology, Inc. (AKTS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.87% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-13
- Aktis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.84%, a 14.09% decline year-over-year.
- Aktis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.47%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month |
|---|---|---|
| 2026-06-30 | 3.87% 10-Q · filed 2026-08-13 | |
| 2026-03-31 | 3.84% 10-Q · filed 2026-05-11 | |
| 2025-06-30 | 4.47% 10-Q · filed 2026-08-13 | |
| 2025-03-31 | 4.47% 10-Q · filed 2026-05-11 |